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calcium homeostasisDysfunction of complex I (CI) of themitochondrial electron transport chain (ETC) features prominently in human
pathology. Cellmodels of ETC dysfunction display adaptive survival responses that still are poorly understood but
of relevance for therapy development. Herewe comprehensively examined how primary human skin ﬁbroblasts
adapt to chronic CI inhibition. CI inhibition triggered transient and sustained changes in metabolism, redox
homeostasis and mitochondrial (ultra)structure but no cell senescence/death. CI-inhibited cells consumed no
oxygen and displayedminor mitochondrial depolarization, reverse-mode action of complex V, a slower prolifer-
ation rate and futile mitochondrial biogenesis. Adaptation was neither prevented by antioxidants nor associated
with increased PGC1-α/SIRT1/mTOR levels. Survival of CI-inhibited cells was strictly glucose-dependent and ac-
companied by increased AMPK-α phosphorylation, which occurred without changes in ATP or cytosolic calcium
levels. Conversely, cells devoid of AMPK-α died upon CI inhibition. Chronic CI inhibition did not increase mito-
chondrial superoxide levels or cellular lipid peroxidation and was paralleled by a speciﬁc increase in SOD2/GR,
whereas SOD1/CAT/Gpx1/Gpx2/Gpx5 levels remained unchanged. Upon hormone stimulation, fully adapted
cells displayed aberrant cytosolic and ER calcium handling due to hampered ATP fueling of ER calcium pumps.
It is concluded that CI dysfunction triggers an adaptive program that depends on extracellular glucose and
AMPK-α. This response avoids cell death by suppressing energy crisis, oxidative stress induction and substantial
mitochondrial depolarization.
© 2014 Elsevier B.V. All rights reserved.ndrialmembranepotential; [ATP]c, free cytosolic ATP concentration; [ATP]m, freemitochondrial ATP concentration; [Ca2+]c, free
Ca2+ concentration; AA, antimycinA; AMPK, AMP-activated protein kinase; AMPK-α, AMPKα -subunit; AscH, ascorbic acid; Bk,
CM-H2DCF, 5-(and-6)-chloromethyl-2',7'-dichlorodihydroﬂuorescein; CS, citrate synthase; CT, vehicle-treated cells; Drp1,
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.J.H. Koopman).
,WeillMedical College of Cornell University, NewYork, NY 10065, USA (FV); Department of Clinical Chemistry, ErasmusMedical
istry (286), Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Centre (RUMC), P.O. Box 9101,
4589; fax: +31 24 3616413.
530 F. Distelmaier et al. / Biochimica et Biophysica Acta 1852 (2015) 529–5401. Introduction
Mitochondria are functionally and morphologically heterogeneous
organelles that are crucially involved in cell metabolism and the sensing
and regulation of calcium signaling [1]. Mitochondrial dysfunction is
associated with a range of human pathologies that often arise as a
consequence of oxidative phosphorylation (OXPHOS) system defects
[2,3]. The OXPHOS system consists of four electron transport chain
(ETC) complexes (CI-CIV) and the ATP-generating FoF1-ATP synthase
(CV). OXPHOS complexes are embedded in the mitochondrial inner
membrane (MIM), which surrounds the mitochondrial matrix
compartment and is itself enveloped by an outer membrane
(MOM). Functionally, protons (H+) are transported out of mitochon-
drial matrix across the MIM by the integrated action of the ETC
complexes. This generates an inward-directed proton-motive force
(PMF), consisting of a proton (ΔpH) and electrical gradient (Δψ).
These gradients sustain ATP production [4] and other mitochondrial
functions, and (co)prevent the release of pro-apoptotic factors [5]. At
the cellular level, OXPHOS dysfunction triggers adaptive programs
that may prevent detrimental cellular consequences and cell death
[6–8]. These programs feature alterations in redox state and
antioxidant responses, mitophagy induction, glycolysis upregula-
tion, changes in mitochondrial morphology and induction of
mitochondrial biogenesis [9]. Adaptation is performed by a complex
network of proteins including AMP-activated protein kinase (AMPK),
peroxisome proliferator–activated receptor γ coactivatorα (PGC-1α), si-
lentmating type information regulation 2 homolog 1 (SIRT1), superoxide
dismutases (SODs), mechanistic target of rapamycin (mTOR) and
mitochondrial ﬁssion and fusion factors [10,11]. Although it has been
proposed that exogenous stimulation of this adaptive network is of
therapeutic value [2,3,12,13], our understanding of this program at the
cellular level is still limited.
Mitochondrial complex I (CI or NADH:ubiquinone oxidoreduc-
tase; EC 1.6.5.3), links NADH oxidation to ubiquinone reduction to
drive H+ transport. CI deﬁciency is the most common cause of
OXPHOS disease in children. Patients with CI deﬁciency frequently
suffer from Leigh or Leigh-like syndrome (OMIM 256000), a severe
neurodegenerative disorder for which currently no cure is available
[14,15]. The pathophysiology of CI deﬁciency has been studied in
patient- and animal-derived cell models [2,14–19]. Cell models
display various physicochemical aberrations including reduced CI
activity, partial Δψ depolarization, increased mitochondrial NADH
levels, elevated reactive oxygen species (ROS) levels and aberrant
calcium (Ca2+) and ATP homeostasis [20]. Importantly, not all cell
parameters (e.g. mitochondrial morphology, ROS levels) are consis-
tently altered in the different cell model systems [15,19,21,22].
These discrepancies likely arise from the use of different cell types,
culture conditions and genetic variability [2,6,9,15,19]. As an alter-
native strategy, cellular adaptation to CI dysfunction can also be
studied using chemical inhibitors [8,23,24]. This approach circum-
vents potential problems associated with inter-patient genetic
variability and allows side-by-side comparison of healthy and
OXPHOS-deﬁcient cells under controlled conditions. Here we
applied the plant alkaloid rotenone (ROT), which binds at the CI
ubiquinone binding site, thereby inhibiting ubiquinone reduction
and CI activity, to gain comprehensive insights into the adaptive
program. Undertaking this approach was triggered by the difﬁculty
of establishing “ideal” controls for studies using patient-derived
cell lines. The latter likely results from individual metabolism-
related genetic variation. Moreover, patient-derived cell lines
represent a “ﬁnal stage” of metabolic adaptation to mitochondrial
dysfunction. This precludes the analysis of the adaptive process in
time. We establish that chronic CI dysfunction induces transient
and sustained cell responses but not cell senescence or death. In
particular, glucose supply and the AMPK α-subunit were proven to be
crucial for cell survival during CI dysfunction.2. Materials and Methods
2.1. Cell culture
Fibroblasts (CT5120) were obtained from a healthy individual
according to the relevant Institutional ReviewBoards. Culturing ofﬁbro-
blasts and HEK 293 cells is described in the Supplement. Immortalized
primary AMPKα1-/-AMPKα2-/- (AMPKα-null) and genetically matched
WT mouse embryonic ﬁbroblasts (MEFs) were cultured as described
previously [25].2.2. Enzyme activities, live-cell oxygen consumption and lactate/pyruvate
measurements
Activity of mitochondrial enzymes, cellular oxygen consumption
and lactate/pyruvate levels in the culture medium were determined as
described in the Supplement.2.3. Fluorescence and bioluminescence analysis of Ca2+ and/or ATP levels
Cytosolic [Ca2+] was quantiﬁed using the ratiometric Ca2+ indicator
fura-2 as described previously [26]. The D1ER Ca2+ sensor protein was
used to monitor ER [Ca2+] as described in the Supplement. Free
cytosolic [ATP] was quantiﬁed using the ATP-sensing protein ATeam
1.03 as described previously [19,21]. Free mitochondrial [ATP] was
measured using a mitochondria-targeted luciferase (mitLUC; [27]).
Details are provided in the Supplement.2.4. Mitochondrial TMRM ﬂuorescence, mitochondrial morphology and
NAD(P)H autoﬂuorescence
Mitochondrial tetramethyl rhodamine methyl ester (TMRM;
Invitrogen) staining was used to estimate mitochondrial membrane
potential, quantify mitochondrial morphology, and analyze mitochon-
drial movement as described previously [28]. TMRM operated in
“non-quenching” mode. Measurement of mitochondrial NAD(P)H
autoﬂuorescence was carried as described previously [29].2.5. ROS levels and cellular lipid peroxidation
ROS levels and lipid peroxidation were quantiﬁed by measuring
the oxidation of hydroethidium (HEt), a mitochondria-targeted
HEt variant (MitoSOX Red), CM-H2DCF (5-(and-6)-chloromethyl-
2',7'-dichlorodihydroﬂuorescein) and C11 BODIPY581/591 (C11), as
described in the Supplement.2.6. Electron microscopy (EM), tubulin staining and Western blot analysis
EM was performed as described previously [30]. Tubulin staining,
Western blotting and antibodies are described in the Supplement.2.7. Image and data analysis
Images were processed and analyzed using Image Pro Plus 6.3
software (Media Cybernetics, Silver Spring, MD, USA). Visualization
of numerical results, curve ﬁtting and statistical analysis was performed
using Origin Pro 7.5 (OriginLab Corp.,Northampton,MA,USA). Unless
stated otherwise, average data is presented as themean± SE (standard
error). Statistical differences were determined using either a two-
population or one-population Student’s t-test (Bonferroni corrected).
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3.1. A cell model to study adaptive responses in CI dysfunction
Primary human skin ﬁbroblasts were cultured in the presence of the
speciﬁc CI inhibitor ROT and used to study adaptive changes. Important-
ly, we used the lowest [ROT] that maximally inhibited CI activity (100
nM; [9,23,30,31]) and analyzed its effects after 72 h and 5 wks. Special
care was taken to prevent artifacts of ﬁbroblast aging during cell culture
and no signs of cell senescence or apoptosis induction were observed
(see Supplement). Within the ﬁrst 2 wks of ROT-treatment twice the
number of cells had to be seeded to reach conﬂuence within a week.
Since cell death was not observed, this indicates that ROT-treated cells
proliferate ~2-fold slower than vehicle-treated (CT) cells. Cell prolifera-
tion remained stable at this reduced rate for the remainder of time. After
5 wks, ROT was removed from the medium and cell proliferation
normalized again within 3 wks. The latter cells are referred to as
“released cells” in the remainder of this study.3.2. CI inhibition blocks cellular O2 consumption, partially depolarizes Δψ
and triggers CV reverse-mode action
Routine cellular O2 consumption was fully inhibited (i.e. identical to
minimal respiration) and FCCP-induced uncoupling failed to stimulate
O2 consumption rate in ROT-treated cells (Fig. 1A). This demonstrates
that the ETC is fully inhibited and suggests that ROT-insensitive
pathways of ETC electron input are absent. Mitochondrial TMRM
ﬂuorescence was reduced by 12% in ROT-treated cells (Fig. 1B). When
the cells were treated with the speciﬁc CIII-inhibitor antimycin A in
the absence of ROT, mitochondrial TMRM ﬂuorescence dropped much
further [9]. Therefore we conclude that Δψ is partially depolarized in
ROT-treated cells. In released cells no Δψ depolarization was observed
(Fig. S1B). This is compatible with previous results indicating that, in
the absence of ETC activity, Δψ can be largely maintained by reverse-
mode action of CV fueled by glycolytic ATP [32]. Detected free ATP levels
in the cytosol ([ATP]c; Fig. 1C) and mitochondrial matrix ([ATP]c;
Fig. 1D) were similar for CT and ROT-treated cells. Relative to CT, total
cellular ATP levels were 2-fold increased in 5 wks ROT-treated ﬁbro-
blasts (Fig. S2E). However the latter cells were 2-fold larger than CT
cells (see below) and therefore the total ATP level is not altered. In CT
cells replacement of extracellular glucose (GLC; 5mM) by the glycolysis
inhibitor 2-Deoxy-D-glucose (2-DG; 5mM) induced a biphasic decay in
[ATP]c (Fig. 1E; arrow continuous line; a, b). When the above maneuver
was performed in the presence of OLI (10 μM, 30 min pre-treatment),
phase-a decay (a’) was not affected whereas phase-b decay (b’) was
3-fold slower (Fig. 1E; dotted line; Fig. 1H). These results suggest that,
during phase-a, sufﬁcient ETC substrates are present to maintain Δψ
and that phase-b starts when these intermediates are depleted and CV
reverse-mode action is triggered. The latter is compatible with the fact
that ROT-treated cells displayed a monophasic [ATP]c decrease
(Fig. 1F-G; continuous lines; c, f). This decrease was up to 3-fold faster
than in CT cells (Fig. 1H), demonstrating that maintaining [ATP]c is
more sensitive to glycolysis inhibition in ROT-treated ﬁbroblasts than
in CT cells. In ROT-treated cells OLI slowed down the 2-DG-induced
[ATP]c decay up to 5-fold (Fig. 1F-G; dotted lines; d, e and g, h). The
[ATP]c curves did not overlap for the ROT and ROT + OLI conditions,
compatible with CV already running in reverse-mode prior to 2-DG
application. In contrast to CT cells, ROT-treated cells died within 24 h
when transferred from the standard GLC-containing culture medium
to a GLC-free galactose(GAL)/glutamine(GLN)-containing medium
(3 independent experiments). These results demonstrate that CI inhibi-
tion induces a strictly glucose-dependent phenotype. Taken together,
the above ﬁndings demonstrate that [ATP]c, [ATP]m and total ATP are
maintained at normal levels by glycolysis in ROT-treated cells and that
ATP is consumed by CV reverse-mode action to largely preserve Δψ.3.3. CI inhibition increases extracellular lactate/pyruvate ratio, alters redox
homeostasis and increases SOD2 and glutathione reductase levels
CT cells released both lactate (L) and pyruvate (P) in the culture
medium and ROT-treatment progressively increased the L/P ratio
(Fig. 2A). A similar increase was observed in mitochondrial NAD(P)H
autoﬂuorescence (Fig. 2B), compatible with reduced CI-mediated
NADH oxidation to NAD+ [33] and/or increased glycolytic NADH
production. Oxidation of the ROS-reporter molecule CM-H2DCF was
similar in CT and ROT-treated cells (Fig. 2C). When excited at
490 nm, oxidation of hydroethidium (HEt) and its mitochondria-
targeted variant MitoSOX Red was increased after 72 h ROT treat-
ment and, to a lesser extent, after 5 wks (Fig. 2D). In released cells
the NAD(P)H level and HEt oxidation normalized again (Fig. S1A).
The ROT-induced increase in MitoSOX Red signal was less than for
HEt, suggesting that HEt oxidation is less speciﬁc for mitochondria-
generated ROS. Using a more superoxide-speciﬁc excitation wave-
length (405 nm) revealed that mitochondrial MitoSOX Red oxidation
was signiﬁcantly increased at 72 h but normal at 5 wks (Fig. 2D).
Cellular lipid peroxidation transiently increased after 72 h (Fig. 2E).
Western blot analysis revealed increased levels of the mitochondrial
manganese (Mn) superoxide dismutase (SOD2) and glutathione
reductase (GR) in ROT-treated cells (Fig. 2F-G). SOD2 plays an im-
portant role in protecting mitochondrial components from superox-
ide mediated damage. GR is an enzyme that catalyzes the reduction
of glutathione disulﬁde (GSSG) to glutathione (GSH), which is a
key cellular antioxidant [34]. These results suggest that CI inhibition
increases mitochondrial superoxide levels and lipid peroxidation,
which are opposed by the action of SOD2 and GR. To determine
whether ROS are mediating adaptation to CI inhibition, ROT-
treated cells were incubated with the antioxidants ascorbic acid
(AscA), Trolox (Tx), N-acetylcysteine (NAC) or the MIM-targeted
antioxidant MitoQ10 for 24 h. No effect on cell survival was observed
(Fig. S2D), possibly suggesting that increased ROS levels are not essen-
tial mediators of adaptation.
3.4. CI inhibition increases cell size and transiently alters mitochondrial
morphology
We previously observed that elevated lipid peroxidation levels
were paralleled by increased mitochondrial length and degree of
branching in 72 h ROT-treated cells [23]. Moreover, alterations in
mitochondrial morphology appear to be linked to CI dysfunction
and ROS levels [22,26,28,35,36]. Relative to CT, 5 wks ROT-treated
cells were 2-fold larger (Fig. 3A-F), contained 2-fold more mitochon-
dria (Fig. 3B-G) and a 2-fold larger endoplasmic reticulum (ER;
Fig. S1D). Cellular hypertrophy was also previously observed in
patient tissues [37] and paralleled by a proportional increase in
levels of the MOM ﬁssion protein Dynamin-related protein 1
(Drp1; Fig. 3K-M), the MOM fusion protein Mitofusin 2 (Mfn2;
Fig. 3K-M) and the MIM fusion protein Optic atrophy protein 1
(OPA1; Fig. 3L-M). In 72 h ROT-treated cells individual mitochondria
were slightly larger (Fig. 3H) and more ﬁlamentous (Fig. 3J). The
latter was associated with increased mitochondrial matrix
connectivity (Fig. S2G). In released cells all mitochondrial morphol-
ogy parameters were normal (Fig. S1B). ROT treatment reduced
mitochondrial motility (Fig. 3C) but did not affect mitochondrial aspect
ratio (Fig. 3I) nor cellular tubulin network organization (Fig. 3D). Al-
though mitochondria possess a less condensed mitochondrial matrix
in glycolytic cancer cells [38], matrix decondensation and ultrastructur-
al alterationswere not observed in ROT-treated cells (Fig. 3E, S3, S5 and
S5). The latter is supported bymatrix protein diffusion analysis in ROT-
treated ﬁbroblasts and cells from CI-deﬁcient patients [30,39]. Compat-
iblewith glycolysis induction (see above), glycogen granuleswere pres-
ent in CT but virtually absent in ROT-treated cells (Fig. 3E, S3, S5 and
S5).
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Fig. 2. Effect of CI inhibition on pyruvate/lactate ratio and redox homeostasis. (A) Lactate/pyruvate (L/P) ratio in the culture medium for CT and ROT-treated cells. (B) Mitochondrial
NAD(P)H levels in CT and ROT-treated cells. (C) Rate of CM-H2DCF oxidation inCT andROT-treated cells. (D) Rate of hydroethidiumandMitoSOXRed oxidation inCT andROT-treated cells
measured using 490 nmor 405 nmexcitationwavelengths (see Results for details). (E) Extent of cellular lipid peroxidation in CT andROT-treated cells. (F) TypicalWestern blotting results
of proteins involved in cellular redox homeostasis including Cu/Zn-Superoxide dismutase 1 (SOD1), Mn-Superoxide dismutase (SOD2), glutathione peroxidase 5 (Gpx 5), glutathione
peroxidase 1 and 2 (Gpx 1/2), Catalase (CAT) glutathione reductase (GR) in whole cell homogenates of CT and ROT-treated cells. Actin was used as a loading control. (G) Quantiﬁcation
ofWestern blotting results regarding the proteins depicted in panel F (n=3). The integrated optical density of the bandswas normalized against actin and expressed as % of CT. Statistics:
***(p b 0.001), **(p b 0.01) and *(p b 0.05) relative to the indicated condition. Numerals reﬂect the number of individual experiments (panel A) or cells (panels B,C,D,E) analyzed on at least
3 different days.
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requires the AMPK-α subunit
Mitochondrial dysfunction is often paralleled by induction of mito-
chondrial biogenesis [40]. ROT-treated cells displayed increased activity
of the mitochondrial matrix enzyme citrate synthase (CS), a commonly
used surrogate marker of mitochondrial volume and content (Fig. S2F).
This was accompanied by elevated protein levels of OXPHOS subunits
(Fig. 4A-B) and increased activity of CII and CIV (Fig. S2F; measured in
isolated mitochondria under Vmax conditions in the absence of ROT).
The p66shc protein displays an inherent ROS-producing capacity,
regulates organismal lifespan and shiftsmetabolism towardsmitochon-
drial respiration [41]. Ser36-phosphorylation of p66shc (P-p66shc) is
stimulated by ROS and increases in mitochondrial disease patientsFig. 1. Effect of CI inhibition on cellular oxygen consumption,mitochondrial membrane po
consumption of control (CT) and ROT-treated ﬁbroblasts (3 independent experiments). (B) Av
images of ATeam-expressing control cells (YFP signal, CFP signal and YFP/CFP ratio). No chan
(D) Average bioluminescence signals of the mitochondrial matrix-targeted ATP sensor luciferas
lowing application of the LUC co-factor luciferin, a steady state level of bioluminescence was rea
themaximal bioluminesce signal obtained after permeabilization of the cells with digitonin in th
and ROT-treated cells (N.S. indicates not signiﬁcant), suggesting that resting [ATP]mwas similar
without (continuous lines) pre-treatment with the CV inhibitor oligomycin A (OLI). During the
glucose (2-DG; vertical arrow). Characters (a, a’, b, b’) mark different kinetic phases of the [AT
as panel E, but now for cells treated with ROT for 72 h. (G) Same as panel E, but now for cells tr
mined by linear ﬁtting (R N 0.98, p b 0.001). The character within each bar corresponds to th
**(p b 0.01) and *(p b 0.05) relative to CT (panel B) or the indicated condition (panels A,C,H).with neuropathy, ataxia and retinitis pigmentosa (NARP; [42]). ROT-
treated cells also showed increased levels of P-p66shc (Fig. 4A-G). Al-
though 5 wks ROT-treated cells displayed elevated levels of OXPHOS
proteins, P-p66shc and CII/CIV enzymatic activity, this adaptation is
likely futile since cell death and O2 consumption were not increased
under these conditions relative to 72 h ROT-treated cells. We also ob-
served a substantial increase in the levels of the AMPK-α subunit
(AMPK-α) and Thr172-phosphorylated AMPK (P-AMPK-α) in ROT
treated cells (Fig. 4C-G). AMPK is a central nutrient and energy sensor
that regulates cellular energy homeostasis [43]. Expression of other im-
portant proteins involved in metabolic regulation was not affected by
ROT treatment (PGC-1α, SIRT1; Fig. 4D-E-G) or not detectable (mTOR;
Fig. 4F-G). Importantly, in the above analysis protein levels and enzy-
matic activity were normalized on cellular actin levels and proteintential and cytosolic free ATP levels. (A) Average routine, leak, maximal and minimal O2
erage mitochondrial TMRM ﬂuorescence in CT and ROT-treated cells. (C) Representative
ges in ATeam ﬂuorescence ratio were detected in ROT-treated cells (lower right panel).
e (mitLUC) for a population (25,000 cells) of control (CT) and ROT-treated ﬁbroblasts. Fol-
ched (upper panel; magniﬁed in lower panel). This signal was expressed as percentage of
e presence of saturating ATP (10mM). Themaximal and resting signal was identical for CT
[71]. (E) Time course of the cytosolic ATeam ratio signal in CT cells with (dotted lines) and
experiment, glucose in the medium was replaced by the glycolysis-inhibitor 2-deoxy D-
P]c decline. Curves reﬂect the average signal for the indicated number of cells. (F) Same
eated with ROT for 5 wks. (H) Rate of decrease of the curves in panels E, F and G, as deter-
e kinetic phase of the ATeam ratio signals in panels E, F and G. Statistics: ***(p b 0.001),
Numerals indicate the number of cells analyzed on at least 2 different days.
Fig. 3. Effect of CI inhibition on cell size,mitochondrial (ultra)structure andmotility, expression ofmitochondrial ﬁssion/fusion proteins and organization of the cellular tubulin
network. (A) Typical microscopy images (linearly contrast optimized for visualization purposes) of CM-DCF-stained CT and ROT-treated cells used to quantify cell size. (B) Typical images
of TMRM-stained CT and ROT-treated cell used to quantify mitochondrial morphology parameters and the number of mitochondria per cell. The image was masked and color-coded to
reﬂect TMRM intensity (blue = low, green = intermediate, red = high). (C) Typical superposition of two images for CT and ROT-treated cells measured at t = 0 (green colored) and
t = 10 min (red colored). The R-value represents Pearson’s R, which reﬂects the colocalization between the green and red pixels in the image (higher R values indicate a higher degree
of colocalization corresponding to reduced mitochondrial movement). (D) Tubulin network organization in typical CT and ROT-treated cells as revealed by immunocytochemistry and
confocal microscopy. (E) Mitochondrial ultrastructure in typical CT and ROT-treated cells revealed by electron microscopy (EM). High-resolution images are provided in the Supplement.
Electron-dense (dark) structures represent glycogen granules. (F) Average cell size of CT and ROT-treated ﬁbroblasts determined by quantitative analysis of CM-DCF-stained cells. (G)
Number of mitochondria per cell (Nc) in CT and ROT-treated cells. (H) Area (Am), reﬂecting the size of individual mitochondria, in CT and ROT-treated cells. (I) Aspect ratio (AR) of indi-
vidualmitochondria in CT and ROT-treated cells. (J) Formfactor (F) of individualmitochondria in CT and ROT-treated cells. (K) Levels of themitochondrial ﬁssion protein Dynamin-related
protein (Drp1; 'b' and 'u' mark the brain and ubiquitous forms of this protein, respectively), themitochondrial fusion proteinMitofusin 2 (Mfn2) and themitochondrial outer membrane
(MOM) protein voltage-dependent anion channel (VDAC) in cytosolic and mitochondria-enriched fractions of CT and ROT-treated cells. Exactly the same amount of protein (20 μg) was
used for each lane. (L) Levels of the mitochondrial inner membrane (MIM) fusion protein Optic atrophy protein 1 (OPA1) in the mitochondrial fraction of CT and ROT-treated cells. Four
OPA1 formswere detected: L(ong)1, L(ong)2, S(hort)4 and S(hort)5. Exactly the same amount of protein (20 μg)was used for each lane. (M) Quantitative analysis of panel K and L. Protein
levels in ROT-treated ﬁbroblasts were expressed relative to those levels in vehicle-treated control (CT) cells on the same blot. ROT treatment particularly increased the levels of Mfn2, mi-
tochondrial Drp1-u and L2-OPA (arrows). Statistics: *(p b 0.05), ***(p b 0.001) relative to CT. Numerals indicate the number of cells analyzed.
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served increases are only a consequence of the ROT-induced increase
in cell size. Both the amount of P-AMPK-α and AMPK-αwere increased
to the same extent (i.e. both proteins showed a 4- to 5-fold increase in
levels in Fig. 4G). This suggests that although the ratio P-AMPK-α/
AMKP-α is not changed, the net levels of P-AMPK-α and AMKP-α are
higher in ROT-treated cells. Given this observation,we next investigated
the role of this protein in more detail using genetically matched wild
type (WT) and AMPK-α1-/-AMPK-α2-/- (AMPK-α-null) mouse embry-
onic ﬁbroblasts (MEFs; [25]). WT MEFs cultured in the presence of
ROT (100 nM, 72 h)were able to proliferate, albeit more slowly, where-
as AMPK-α-null MEFs did not survive (Fig. 5). This demonstrates that
AMPK-α is crucial for cell adaptation and survival during CI inhibition.
3.6. CI inhibition slows endoplasmic reticulum Ca2+ reuptake after
hormone stimulation
To determine how adapted cells coped with conditions of increased
ATP demand, cells were stimulated with the hormone bradykinin (Bk;
[27]), which triggers Ca2+ release from the endoplasmic reticulum(ER) and stimulates ATP-consuming Ca2+-ATPases at the plasma
membrane (PMCAs) and the sarco/endoplasmic reticulum (SERCAs).
In CT ﬁbroblasts, Ca2+ enters the mitochondrial matrix and increases
ETC-mediated ATP production, which is primarily used for SERCA
fueling [44,45]. In 5 wks ROT-treated cells ER Ca2+ uptake (Fig. 6A-B)
and rate of cytosolic Ca2+ removal (Fig. 6C-D) were reduced. ROT-
treatment did not affect resting ER [Ca2+] ([Ca2+]ER; Fig. S1E), the rate
of ER Ca2+ release (Fig. S1F), the extent of ER reﬁlling after Bk stimula-
tion (Fig. S1E), the resting cytosolic [Ca2+] ([Ca2+]c; Fig. S1G), or the
amplitude of the [Ca2+]c signal (Fig. S1H). These results suggest that
glycolytic ATP generation sufﬁces to sustain normal ER and cytosolic
Ca2+ levels under resting conditions in ROT-treated and fully adapted
cells. However, this adaptation does not allow for proper ATP fueling
of SERCAs upon cell stimulation.
4. Discussion
In this study we aimed to gain comprehensive insights into the
adaptive program triggered bymitochondrial CI dysfunction in primary
human skin ﬁbroblasts (Fig. 7). To circumvent potential problems
Fig. 4. Effect of CI inhibition on the levels of OXPHOS and metabolic proteins. (A) Western blotting results of OXPHOS proteins and Ser36-phosphorylated p66shc (P-p66shc). (B)
Quantiﬁcation of Western blotting results regarding the OXPHOS proteins depicted in panel A. The integrated optical density of the bands was normalized against actin and expressed
as % of CT on the same blot. (C) Western blot analysis of AMP-activated protein kinase α-subunit (AMPK-α) and Thr172-phosphorylated AMPK-α (P-AMPK-α). (D) Same as panel C
but now for peroxisome proliferator–activated receptor γ coactivator α1 (PGC-1α). A whole-cell homogenate derived from HEK293 cells was included as a positive control. (E) Same
as panel D but now for silent mating type information regulation 2 homolog 1 (SIRT1). (F) Same as panel D but now for mechanistic target of rapamycin (mTOR). (G) Same as panel B
but now for the Western blots in panels A (P-p66shc), C, D, E and F. Statistics: *(p b 0.05), **(p b 0.01) relative to CT. For borderline signiﬁcant changes the exact p-values are given.
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allow time-dependent analysis we here chose to use a chemical
inhibitor (ROT) to induce CI dysfunction. It is demonstrated that chronic
CI inhibition is reversible, fully blocks ETC function and induces a non-Fig. 5. Effect of CI inhibition in AMPK-α-KO mouse embryonic ﬁbroblasts. Typical images
(AMPK-α1-/-AMPK-α2-/-) MEFs under various experimental conditions (two independent exp
or ROT. Genetically matchedWTmouse embryonic ﬁbroblasts survived ROT treatment, wheresenescent phenotype that is characterized by a partially depolarized
Δψ, CV reverse-mode action but normal resting ATP levels. Also other
transient and sustained cell responses were observed and extracellular
GLC and the AMPK α-subunit appeared to be crucial for cell survivaldepicting the cell culture of WT mouse embryonic ﬁbroblasts (MEFs) and AMPK-α-null
eriments) directly after seeding the cells (T0) and 72 h of treatment with vehicle (VEH)
as AMPK-α-null MEFs did not.
Fig. 6. Effect of CI inhibition on Ca2+ and ATP homeostasis in hormone-stimulated cells. (A) Average time traces of the D1ER ratio, reﬂecting free [Ca2+] in the ER ([Ca2+]ER), in CT and
ROT-treated cells. Horizontal bars mark the extracellular application of the hormone bradykinin (Bk) and the Ca2+ ionophore ionomycin (Iono). (B) Time required for half-maximal re-
covery of [Ca2+]ER after Bk removal, determined by ﬁtting a Boltzmann equation (y = {(A1-A2)/(1 + EXP[(x-x0)/dx])} + A2) to the rising phase of the curve in panel A for CT and ROT-
treated cells. R2 values were: 0.99 (CT), 0.99 (ROT (72 h)) and 0.99 (ROT (5 wks)). (C) Average Bk-induced change in fura-2 ratio, reﬂecting the free [Ca2+] in the cytosol ([Ca2+]c) for CT
and ROT-treated cells. (D) Time constant of [Ca2+]c decay (larger means slower), determined from a mono-exponential ﬁt to the decay phase of the fura-2 signal in panel C (R2 N 0.95).
Statistics: **(p b 0.01) and ***(p b 0.001) relative to CT. Numerals indicate the number of individual cells. Experimental data was obtained in at least 3 independent experiments.
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cells induced aberrant Ca2+ signals. This suggests that ATP fueling of
endoplasmic reticulum calcium pumps is hampered.
4.1. CI inhibition blocks ETC activity and induces partial Δψ depolarization
and CV reverse-mode action but does not affect ATP levels
In ROT-treated cells, routine, leak, maximal and minimal cellular O2
consumption were identical. This means that ETC-dependent O2
consumption and ATP production are blocked in ROT-treated cells.
These ﬁndings suggest that CII, which is part of both the ETC and
TCA-cycle, is not actively contributing to O2 consumption in ROT-
treated cells. The latter might result from the increased NADH levels
in the mitochondrial matrix, leading to inhibition of the TCA cycle.
In contrast, HEK293 cells that were chronically treated with ROT
still displayed CII-mediated residual O2 consumption [21]. This
difference likely relates to the observation that the cellular “context”(e.g. cell immortalization, external glucose concentration, culture condi-
tions, cell type, cell metabolic state) appears to affect the cellular conse-
quences of genetic and inhibitor-induced CI deﬁciency [46]. In the fully
adapted state,Δψwas largely maintained by CV reverse-mode action in
ROT-treated ﬁbroblasts. This is important since Δψ is required for mito-
chondrial substrate/ion-exchange, protein import and mitochondrial
fusion (see [9] and the references therein). In resting ROT-treated
cells, no change in [ATP]c, [ATP]m and total-cell ATP levelswas observed,
demonstrating that the reduction in mitochondrial ATP production is
fully compensated for.
4.2. CI inhibition induces a fully glycolytic phenotype
ROT-treated cells displayed a reduction in glycogen granules and an
increased L/P ratio in the culture medium. This is compatible with
stimulation of the glycolysis pathway. Such an increase was previously
linked to the presence of a respiratory chain defect in cultured
Fig. 7. Cellular consequences of CI inhibition and proposed adaptive mechanism in primary human skin ﬁbroblasts. Chronic inhibition (5 wks) of mitochondrial complex I (CI) by
rotenone (ROT) induces cellular consequences that trigger an adaptive response programme. These two phenomena are associated with various alteration in bioenergetics, cell growth,
redoxmetabolism, cell structure,mitochondrial (ultra)structure and calcium homeostasis. The adaptive response prevents cell death by limiting or preventing the detrimental effects of CI
dysfunction. We here demonstrate that cells in which CI is chronically and completely inhibited strictly depend on extracellular glucose (GLC) for their survival. Also genetic ablation of
AMPK-α was lethal in ROT-treated but not wild type mouse embryonic ﬁbroblasts. We further demonstrate that various exogenously-added antioxidants were unable to prevent the
survival of ROT-treated cells, suggesting that ROS do not play a key role in the adaptive response.
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lactate levels, the values obtained for CT cells in this study (~8 mM)
closely matches those presented previously [48]. Although cells can
take up pyruvate from the culture medium [49], adherent human skin
ﬁbroblasts can also release pyruvate [50]. In our study the culturemedi-
umdid not contain pyruvate.Weobserved that CT and 72hROT-treated
ﬁbroblasts released ~0.2 mM of pyruvate into the medium during a
period of 72 h, compatible with previous results [50]. The amount of
pyruvate in the medium was 2-fold lower in cells treated for 5 wks
with ROT (i.e. ~0.10 mM), suggesting that less pyruvate is released
and more pyruvate is metabolized by the cell at this time. CT cells
survived in a GAL/GLN-containing medium without GLC. Although
GLN was also present in the normal GLC-containing medium, cells
preferentially consume GLC under these conditions [38,51,52]. GAL
enters the glycolysis through the Leloir pathway and this occurs at a
signiﬁcantly lower rate than GLC entry in glycolysis. The residual levels
of glycolytic intermediates produced by GAL metabolism are funneled
into the pentose phosphate pathway [52–54]. Therefore, similar to
certain cancer cells [38], ﬁbroblasts in GAL/GLN medium rely on
GLN-driven mitochondrial ATP production [55]. GLN, essential for cell
growth, is taken up by the cell and converted to glutamate (GLU) in
the mitochondrial matrix. In cancer cells, GLN also provides a source
of reduced nitrogen allowing nucleotide production and non-essential
amino acids. Additionally, GLN plays a role in the uptake of essential
amino acids, can maintain the TCA cycle when GLC levels are limiting
and can support NADPH production. The latter is necessary for lipid
and nucleotide biosynthesis and antioxidant recycling [9,56]. In contrast
to CT cells, ROT-treated cells cannot survive without GLU because
glutaminolysis requires an active ETC for ATP production. It is unlikely
that ATP is supplied by β-oxidation-mediated production of acetyl-
Coenzyme A since this route also requires an active ETC. From the
above, we conclude that ROT-treated human skin ﬁbroblasts have
switched to a fully glycolytic phenotype.4.3. CI inhibition induces a transient increase in mitochondrial ROS levels
and cellular lipid peroxidation
Impairment of mitochondrial function has been linked to increased
ROS levels and oxidative stress induction, potentially playing a role in
mitochondrial disease progression. The current study demonstrates
that ROT-induced CI inhibition stimulates HEt and MitoSOX Red oxida-
tion after 72 h of treatment. However, HEt and MitoSOX Red oxidation
were signiﬁcantly lower after 5 wks than after 72 h of ROT treatment.
When amore speciﬁc detectionmethod for quantiﬁcation of mitochon-
drial superoxide levels was applied (i.e. measuring MitoSOX Red
oxidation products at 405 nm excitation; [57,58]), no signiﬁcant in-
crease was detected after 5 wks of ROT treatment. Similarly, cellular
lipid peroxidation was increased after 72 h ROT treatment and normal
again after 5 wks. Superoxide is detoxiﬁed by the action of superoxide
dismutases (SODs) present in the IMS/cytosol (SOD1 or CuZnSOD)
and in the mitochondrial matrix/MIM (SOD2 or MnSOD). Compatible
with the normalization of mitochondrial superoxide levels and absence
of lipid peroxidation in 5 wks ROT-treated cells, ROT treatment speciﬁ-
cally increased SOD2 levels but not SOD1 levels. These results suggest
that CI inhibition increases mitochondrial superoxide levels and lipid
peroxidation, which are opposed by adaptive upregulation of SOD2
and GR. In addition, SOD2 upregulationmight be involved in preserving
the proliferative capacity of human ﬁbroblasts [59].4.4. CI inhibition transiently alters mitochondrial structure and matrix
connectivity
72 h ROT treatment induced an increase in mitochondrial length,
degree of branching and matrix connectivity, whereas 5 wks ROT
treatment led to a 2-fold increase in the number of mitochondria
per cell, without alterations in mitochondrial shape. We previously
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a protective mechanism, for instance to share oxidative damage and
antioxidants [35]. This idea is supported by the observation that cells
display increased mitochondrial fusion leading to a closed network
when subjected tomodest levels of stress [60].Moreover,mitochondrial
networking protected β-cells from nutrient-induced apoptosis [61].
4.5. CI inhibition induces cell hypertrophy but not cell senescence
ROT-treated ﬁbroblasts ultimately displayed a 2-fold increase in cell
size, paralleled by proportional increases in the number of mitochondria,
ER size and total-cell ATP levels. In heart, hypertrophy can be physiolog-
ical or pathological, depending on the nature of the stimulus (e.g. adapta-
tion to training vs. hypertension), and is characterized by cardiomyocyte
enlargement [62]. Cardiac hypertrophy, as well as mitochondrial (hyper)
biogenesis ('ragged red ﬁbers') in skeletal muscle biopsies, was also ob-
served in childrenwith inherited isolatedCI deﬁciency [14]. In compensa-
tive cardiac hypertrophy it appears that cardiac mass and mitochondrial
content/function increase in parallel, whereas during progression to
heart failure decreased mitochondrial biogenesis and oxidative capacity
are observed [62]. In contrast to senescence ﬁbroblasts can also display
quiescence, a reversible growth/proliferation arrest induced by mitogen
(serum) withdrawal, contact inhibition or loss of adhesion [7]. In the
current study, special care was taken to keep cell cultures sub-conﬂuent
to prevent contact inhibition-induced quiescence. Primary human ﬁbro-
blasts display high metabolic rates when induced into quiescence via
contact inhibition [63,64]. Contact-inhibited cells displayed lower glucose
consumption, reduced lactate secretion, and a smaller size. All of these
features were not observed in ROT-treated cells, strongly suggesting
that these cells are not quiescent.
4.6. CI inhibition activates AMPK
We observed a 5-fold increase in the levels of AMPK-α and Thr172-
phosphorylation AMPK-α (P-AMPK) in CI-inhibited cells. Moreover,
AMPK-α-null MEFs did not survive upon ROT-induced CI inhibition.
AMPK activation (phosphorylation) serves to maintain cellular energy
stores by initiating metabolic and genetic events that restore ATP levels
by switching on ATP-generating catabolic pathways (e.g. glycolysis,
OXPHOS, fatty acid oxidation and glucose uptake) while inhibiting
others that consume ATP but are not acutely required for survival (e.g.
triglyceride/protein synthesis, fatty acid synthesis, glycogen synthesis,
cholesterol synthesis and cell proliferation) [11,65–67]. AMPK-α phos-
phorylation is primarily mediated by serine-threonine liver kinase B1
(LKB1), which is stimulated by an increase in [AMP]. In addition,
Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) phos-
phorylates AMPK when intracellular Ca2+ levels increase [66]. Any cel-
lular stress that reduces the cellular [ATP] and decreases the [ATP]/
[ADP] ratio will, via adenylate kinase, result in a much larger increase
in the [AMP]/[ATP] ratio and thereby induce AMPK-α phosphorylation
[68]. Experimental evidence further suggests that also ROS can induce
AMPK activation [67,69,70]. In the current study we did not observe
increased [Ca2+]c or reduced ATP levels in fully adapted CI-inhibited
cells. Also various antioxidant treatments did not prevent survival of
ROT-treated ﬁbroblasts. Taken together, we conclude that AMPK-α
phosphorylation is a crucial mediator of the adaptive response in CI-
inhibited cells and suggest that this activating phosphorylation is
stimulated by a “non-classical” pathway. The latter could involve upreg-
ulation of AMPK gene expression at the transcriptional level, in which
mitochondrial NAD(P)H might play a role.
4.7. CI inhibition impairs hormone-stimulated Ca2+ signals in fully adapted
cells
Upon Bk stimulation, the rate of ER Ca2+ release was identical in
CI-inhibited and CT ﬁbroblasts. Similarly, no difference was observedin the pre-Bk resting [Ca2+]c, the pre-Bk resting [Ca2+]ER, and the
amplitude of the [Ca2+]c transient. Moreover, [Ca2+]ER returned to
similar levels in CI-inhibited and CT cells after Bk-stimulation. Collec-
tively these results suggest that the ER Ca2+ content (ERCa) is not af-
fected by chronic CI inhibition. After reaching a peak value, [Ca2+]c
returned to basal levels with mono-exponential kinetics. [Ca2+]c
decay and SERCA-mediated ER Ca2+ uptake were signiﬁcantly slower
in ROT-treated cells leading to a protracted [Ca2+]c transient. These re-
sults demonstrate that glycolysis-generated ATP sufﬁces to maintain
normal ERCa in resting CI-inhibited ﬁbroblasts. However, when ATP de-
mand is acutely increased by Bk application, Ca2+-stimulated ETC-
mediated ATP production cannot be activated in CI-inhibited cells.
Since this mitochondrial ATP is primarily used for SERCA fueling [44,
45], CI-inhibited cells display aberrant [Ca2+]c decay kinetics.
5. Conclusions
Our results in primary human skin ﬁbroblast suggest a model in
which CI inhibition fully blocks ETC activity and triggers an adaptive
survival program (Fig. 7). As previously reviewed [9], the ﬁbroblast
ROT model displays several aberrations also induced by ROT treatment
in other cell types (e.g. increased ROS levels), ﬁbroblasts from patients
with inherited CI deﬁciency (e.g. increased ROS, elevated NAD(P)H
levels, aberrant Ca2+ handling, partial Δψ depolarization) and primary
CI-deﬁcient mouse ﬁbroblasts and myoblasts (e.g. increased ROS) [9,
23,46]. Adaptation did not require upregulation of PGC1-α, SIRT1 or
mTOR but involved increased expression of (phosphorylated) AMPK-
α. The importance of the latter protein is supported by the fact that
CI-inhibition in AMPK-α-null MEFs was lethal. Although the exact
mechanism of AMPK activation in CI-inhibited cells is still unclear, “clas-
sical” activators (i.e. a reduction in ATP amount or increased [Ca2+]c
levels) were not observed. To suppress mitochondrial superoxide levels
and cellular lipid peroxidation, chronic CI inhibition was paralleled by
upregulation SOD2 and GR. Moreover, various antioxidants did not trig-
ger cell death in CI-inhibited cells. This suggests that ROS-signaling is
not essential to keep the adaptive program in an activated state. CI-
inhibited ﬁbroblasts became hypertrophic, displayed (futile) mitochon-
drial biogenesis and fully depended on glycolysis for ATP production.
This ATP was used to fuel reverse-mode action of CV to maintain Δψ,
which allows mitochondria to sustain various mitochondrial processes
like substrate and ion-exchange, protein import and mitochondrial fu-
sion. The adaptive program was unable to compensate for the lack of
Ca2+-stimulated mitochondrial ATP generation during cell stimulation.
This highlights the crucial role ofmitochondriawhen the cell faces acute
increases in ATP demand.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.12.012.
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